A study by Donnan et al., however, reported that evidence from randomized control trials (RCTs) does not indicate an increased risk of harm with SGLT2 inhibitors compared with placebo or active comparators, with respect to AKI, DKA, UTI, or fracture. The gene discussed is SLC5A2; the disease is acute kidney injury.